Yohimbine for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Yohimbine for Health & Longevity

Created on 09/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Yohimbine, a stimulant tree-bark compound sold as a supplement for fat loss and male sexual performance, removes a natural brake on fight-or-flight signals. In men with erection problems, studies show real but modest improvement; it also raises standing blood pressure when automatic blood-pressure nerves fail. Fat-loss evidence is thin. Anxiety, panic, blood-pressure and heart-rate rises are well documented. For longevity-minded adults, value rests on narrow uses, not general health benefit. (Full Review)

Protocol

Starting dose
2.5 mg
Increasing by 2.5 mg every few days toward the target if blood pressure and anxiety remain acceptable; morning dosing
Fat-loss protocol
0.2 mg/kg daily
Yohimbine hydrochloride split into 2–3 doses, taken fasted, often 15–30 min before training
Erectile dysfunction protocol
5.4 mg three times daily
Or 15–30 mg daily in trials, for 6–10 weeks
Time to effect
Erectile function
6–10 weeks
Benefit assessed after daily use in trials
Standing blood pressure
30–60 min
Blood-pressure effects begin after a dose
Fat loss
3 weeks
Fat-loss differences appeared; fat release begins within 30–60 min

Benefits

Contraindications
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline): absolute contraindication outside specialist care
  • Uncontrolled hypertension (resting blood pressure at or above 140/90 mmHg despite treatment)
  • Coronary artery disease, heart attack within the past 6 months, arrhythmia, or heart failure (NYHA class II–IV)
  • Panic disorder, post-traumatic stress disorder, generalized anxiety disorder, or bipolar disorder
  • Seizure disorders
  • Pregnancy and breastfeeding
  • Liver cirrhosis (Child-Pugh class B or C) or kidney disease (eGFR below 30 mL/min/1.73 m²)
  • Known CYP2D6 poor metabolizers taking standard doses
  • People on methadone or buprenorphine for opioid dependence
  • Children and adolescents under 18 years
    •
Key Interactions
  • Tricyclic antidepressants (clomipramine, amitriptyline, imipramine): caution
  • Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine): major caution
  • Central alpha-2 agonists (clonidine, guanfacine, methyldopa): avoid
  • Other antihypertensives (lisinopril, amlodipine, losartan): monitor
  • Beta blockers (propranolol, metoprolol): caution
  • Prescription stimulants (amphetamine, methylphenidate, modafinil): avoid
  • Phosphodiesterase-5 inhibitors (sildenafil, tadalafil): monitor
  • Methadone and other opioid therapies: avoid
  • Over-the-counter decongestants and stimulants (pseudoephedrine, phenylephrine, caffeine tablets): caution
  • Over-the-counter CYP2D6 inhibitors (diphenhydramine): monitor
  • Stimulant supplements with additive effects (caffeine, guarana, synephrine, rauwolscine, higenamine, ephedra): avoid stacking
  • Supplements that raise blood pressure (licorice root containing glycyrrhizin): caution
  • Fasting and alcohol: monitor
    •

Risk & Side Effects

  • High: Anxiety, nervousness and panic attacks; blood pressure and heart rate increase
    •
  • Medium: Gastrointestinal distress; severe toxicity from supplement products
    •
  • Low: Immune-mediated skin and kidney reactions; headache, flushing, frequent urination and sleep disturbance; heart-rhythm disturbances; heart attack; manic symptoms; priapism
    •
  • Speculative: Direct heart-cell electrical toxicity
    •

Monitoring

Marker Target Why
Resting blood pressure Below 120/80 mmHg Detects pressure rise
Standing blood pressure Drop under 20/10 mmHg Detects postural drop; tracks benefit
Resting heart rate 50–70 beats/min Detects stimulant excess
ECG Normal sinus rhythm; QTc under 440 ms (men), 460 ms (women) Baseline rhythm check
Fasting glucose 75–90 mg/dL Yohimbine alters insulin release
ALT Below 25 U/L Liver clears yohimbine
eGFR Above 90 mL/min/1.73 m² Kidney injury case reports
CYP2D6 genotype Normal metabolizer Predicts blood levels
Body composition (DEXA) No established target; track change from own baseline Measures fat-loss effect
Erectile function (IIEF-5) 22–25 points Tracks sexual benefit
Anxiety (GAD-7) 0–4 points Detects anxiety side effects

Cadence: Home blood pressure and heart rate before and 60 minutes after the first doses, then weekly for 4 weeks, then monthly; questionnaires at 4 and 8 weeks; body composition at 8–12 weeks; liver and kidney tests every 6–12 months during long-term use

Qualitative Assessment

  • Energy and alertness without jitteriness
  • Anxiety, restlessness or palpitations
  • Sleep onset and quality
  • Waist circumference and clothing fit
  • Erection quality and sexual satisfaction
  • Dizziness on standing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.